Bearing in mind a recent study suggesting that LL-37 derived from LL37-DNA complexes attacks mycobacteria in macrophage phagolysosomes (38), we could assume that clarithromycin-induced NET-bound LL-37 enhances the efficiency of macrophages of T2D patients against intracellular bacteria, as well. The gene discussed is CAMP; the disease is type 2 diabetes mellitus.